NO952781L - Potensiering av temozolomid i humane tumorceller - Google Patents

Potensiering av temozolomid i humane tumorceller

Info

Publication number
NO952781L
NO952781L NO952781A NO952781A NO952781L NO 952781 L NO952781 L NO 952781L NO 952781 A NO952781 A NO 952781A NO 952781 A NO952781 A NO 952781A NO 952781 L NO952781 L NO 952781L
Authority
NO
Norway
Prior art keywords
temozolomide
potentialization
tumor cells
human tumor
atase
Prior art date
Application number
NO952781A
Other languages
English (en)
Norwegian (no)
Other versions
NO952781D0 (no
Inventor
John Colin Baer
Azadeh Alison Freeman
Edward Stuart Newlands
Amanda Jean Watson
Joseph Anthony Rafferty
Geoffrey Paul Margison
Original Assignee
Cancer Res Campaign Tech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Res Campaign Tech filed Critical Cancer Res Campaign Tech
Publication of NO952781D0 publication Critical patent/NO952781D0/no
Publication of NO952781L publication Critical patent/NO952781L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
NO952781A 1993-01-14 1995-07-13 Potensiering av temozolomid i humane tumorceller NO952781L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US475493A 1993-01-14 1993-01-14
PCT/GB1994/000065 WO1994015615A1 (en) 1993-01-14 1994-01-13 Potentiation of temozolomide in human tumour cells

Publications (2)

Publication Number Publication Date
NO952781D0 NO952781D0 (no) 1995-07-13
NO952781L true NO952781L (no) 1995-09-13

Family

ID=21712364

Family Applications (1)

Application Number Title Priority Date Filing Date
NO952781A NO952781L (no) 1993-01-14 1995-07-13 Potensiering av temozolomid i humane tumorceller

Country Status (20)

Country Link
EP (2) EP0922458A1 (zh)
JP (1) JPH08505615A (zh)
KR (1) KR100352046B1 (zh)
CN (1) CN1277541C (zh)
AU (1) AU5838494A (zh)
CA (1) CA2153775C (zh)
CZ (1) CZ286550B6 (zh)
FI (1) FI953423A (zh)
HU (1) HUT72665A (zh)
IL (1) IL108328A (zh)
MX (1) MX9400434A (zh)
MY (1) MY116474A (zh)
NO (1) NO952781L (zh)
PL (1) PL175842B1 (zh)
RU (1) RU2148401C1 (zh)
SK (1) SK282452B6 (zh)
TW (1) TW414710B (zh)
UA (1) UA29466C2 (zh)
WO (1) WO1994015615A1 (zh)
ZA (1) ZA94248B (zh)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5731304A (en) * 1982-08-23 1998-03-24 Cancer Research Campaign Technology Potentiation of temozolomide in human tumour cells
US5942247A (en) * 1996-07-31 1999-08-24 Schering Corporation Method for treating pediatric high grade astrocytoma including brain stem glioma
US5939098A (en) * 1996-09-19 1999-08-17 Schering Corporation Cancer treatment with temozolomide
US6251886B1 (en) 1998-12-07 2001-06-26 Schering Corporation Methods of using temozolomide in the treatment of cancers
WO2000033823A2 (en) * 1998-12-07 2000-06-15 Schering Corporation Methods of using temozolomide in the treatment of cancers
US6465448B1 (en) * 1999-08-13 2002-10-15 Case Western Reserve University Methoxyamine potentiation of temozolomide anti-cancer activity
US6635677B2 (en) 1999-08-13 2003-10-21 Case Western Reserve University Methoxyamine combinations in the treatment of cancer
SG161101A1 (en) * 2002-02-22 2010-05-27 Schering Corp Pharmaceutical formulations of antineoplastic agents, in particular temozolomide processes of making and using the same
WO2003101474A1 (en) * 2002-05-31 2003-12-11 Transmolecular, Inc. Combination chemotherapy with chlorotoxin
CN100350975C (zh) * 2005-02-03 2007-11-28 山东蓝金生物工程有限公司 抗癌药物组合物
CN100350974C (zh) * 2005-02-03 2007-11-28 山东蓝金生物工程有限公司 一种抗癌药物组合物
CN100431605C (zh) * 2005-02-03 2008-11-12 山东蓝金生物工程有限公司 一种抗癌药物组合物
CN100402091C (zh) * 2005-02-03 2008-07-16 山东蓝金生物工程有限公司 一种抗癌药物组合物
GB0502573D0 (en) * 2005-02-08 2005-03-16 Topotarget As Therapeutic compounds
WO2008022535A1 (fr) * 2006-08-09 2008-02-28 Tian Jin Tasly Group Co., Ltd. Composition pharmaceutique pour traiter le gliome du cerveau, son procédé et sa préparation pharmaceutique
CA2724384A1 (en) 2008-05-15 2009-11-19 Transmolecular, Inc. Treatment of metastatic tumors
DK2531206T3 (en) 2010-02-04 2017-09-11 Morphotek Inc CHLOROTOXIN POLYPEPTIDES AND CONJUGATES AND USE THEREOF
KR101972173B1 (ko) 2010-05-11 2019-04-24 프레드 헛친슨 켄서 리서치 센터 클로로톡신 변이체, 접합체, 및 이의 사용 방법
CN103169664B (zh) * 2011-12-25 2015-04-22 复旦大学 一种rgd肽修饰的双层载药纳米粒及其制备方法
CA2913029A1 (en) 2012-12-10 2014-06-19 Fred Hutchinson Cancer Research Center Lipocalin fusion partners
US11559580B1 (en) 2013-09-17 2023-01-24 Blaze Bioscience, Inc. Tissue-homing peptide conjugates and methods of use thereof
WO2017181149A1 (en) 2016-04-15 2017-10-19 Blaze Bioscience, Inc. Methods of treating breast cancer

Also Published As

Publication number Publication date
TW414710B (en) 2000-12-11
JPH08505615A (ja) 1996-06-18
CA2153775C (en) 2000-11-14
CZ286550B6 (cs) 2000-05-17
RU2148401C1 (ru) 2000-05-10
WO1994015615A1 (en) 1994-07-21
IL108328A0 (en) 1994-04-12
CN1117711A (zh) 1996-02-28
PL309915A1 (en) 1995-11-13
KR100352046B1 (ko) 2003-09-03
ZA94248B (en) 1994-07-13
FI953423A0 (fi) 1995-07-13
HU9502117D0 (en) 1995-09-28
CA2153775A1 (en) 1994-07-21
AU5838494A (en) 1994-08-15
HUT72665A (en) 1996-05-28
EP0679086A1 (en) 1995-11-02
UA29466C2 (uk) 2000-11-15
CZ179795A3 (en) 1996-04-17
FI953423A (fi) 1995-08-23
PL175842B1 (pl) 1999-02-26
EP0922458A1 (en) 1999-06-16
SK89295A3 (en) 1996-06-05
KR960700063A (ko) 1996-01-19
IL108328A (en) 2010-05-31
MX9400434A (es) 1994-07-29
NO952781D0 (no) 1995-07-13
MY116474A (en) 2004-02-28
SK282452B6 (sk) 2002-02-05
CN1277541C (zh) 2006-10-04

Similar Documents

Publication Publication Date Title
NO952781L (no) Potensiering av temozolomid i humane tumorceller
DE69427862D1 (de) K-252a derivate, die neurotrophin-induzierte aktivität erhöhen
NO932954D0 (no) 2,4-diaminokinazolin-derivater for aa oppnaa oeket antitumoraktivitet
TR200200160T2 (tr) Antiinflamatuar ajanlar olarak imidazoller ve triazoller
ES2074867T3 (es) Derivados de quinazolina para potenciar la actividad antitumoral.
PT907652E (pt) Compostos e processos imunossupressores
TR199800012T1 (xx) Piroloprimidinler ve preparasyon i�in tatbikler.
ES2089687T3 (es) 4-fenil-piridonas y 4-fenil-2-alcoxipiridinas sustituidas como inhibidores de la hmg-coa-reductasa.
ATE240334T1 (de) Pyrrolobenzodiazepine
ES2174863T3 (es) Compuestos de pirimidina y su uso como compuestos farmaceuticos.
EA200501253A1 (ru) Производные пиразоло[1,5-a][1,3,5]триазина в качестве лигандов каннабиноидных рецепторов
ATE387450T1 (de) Meso-substituierte porphyrine
BR0108715A (pt) Compostos de 3,4-diidro-1h-pirimido[4,5-d]-pirimidin-2-ona 1,5-dissubstituìdos e seu uso no tratamento de doenças mediadas pela cinase csbp/p38
HRP20050387A2 (en) DERIVATIVES OF [6,7-DIHYDRO-5H-IMIDAZO[1,2-α] IMIDAZOLE-3-SULFONYLAMINO]-PROPIONAMIDE
IT1264530B (it) Impiego dei polisaccaridi nelle neuropatie atrofico degenerative
EA200200808A1 (ru) Модифицированные цитокины, предназначенные для применения в терапии рака
DK0869965T3 (da) Steroidnitritesterderivater anvendelige som antiinflammatoriske lægemidler
MXPA03003923A (es) Compuestos de n-([1,2,4]triazoloazinil)tiofensulfonamida como herbicidas.
PT983272E (pt) Nova classe de compostos fotoactivos derivados de benzoporfirina
NO890046L (no) Disubstituerte pyridiner.
ES2218814T3 (es) Uso de queleritrina y radiacion para el tratamiento de tumores.
NL180893C (nl) Stelsel voor het opwekken van een elektronenbundel voor toepassing bij de fabrikage van geintegreerde ketens.
ES2068714T3 (es) Derivados de pirimidina para aumentar la actividad antitumoral.
BR0015402A (pt) Derivados de ácido 15-hidroxieicosatetraenóico de cadeia Èmega modificada e métodos de seu uso para o tratamento de olho seco
GR3017967T3 (en) Substituted pyrido-oxazines.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application